{"id":554136,"date":"2026-06-25T21:32:26","date_gmt":"2026-06-25T21:32:26","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/554136\/"},"modified":"2026-06-25T21:32:26","modified_gmt":"2026-06-25T21:32:26","slug":"3-companies-redefining-healthcare-innovation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/554136\/","title":{"rendered":"3 Companies Redefining Healthcare Innovation"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article was originally published on <a href=\"https:\/\/www.etftrends.com\/disruptive-technology-content-hub\/3-companies-redefining-healthcare-innovation\/?utm_source=Yahoo&amp;utm_medium=referral&amp;utm_campaign=ReadMore\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:ETFTrends.com.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;ETFTrends.com.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">ETFTrends.com.<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The <a href=\"https:\/\/www.vettafi.com\/indexing\/index\/htec\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Healthcare%20Technology%20and%20Innovation%20index%20(HTEC);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Healthcare Technology and Innovation index (HTEC)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Healthcare Technology and Innovation index (HTEC)<\/a> was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address critical societal challenges. Issues such as an aging population, rising medical costs, and a shortage of skilled healthcare workers drove the creation of the index back then, and they remain just as relevant today.  <\/p>\n<p>            <strong>Key Takeaways:<\/strong>      <\/p>\n<ul class=\"yf-1jsc1up\">\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">CRISPR Therapeutics, co-developer of the CASGEVY gene-editing cure for sickle cell disease and beta-thalassemia, was added to HTEC. The company brings an advanced pipeline of therapies targeting cardiovascular and autoimmune diseases.  <\/p>\n<\/li>\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Insilico Medicine joins HTEC as its first pure-play AI drug discovery company, generating 6 to 8 preclinical candidates annually and projecting $1,287MM in FY 2026 revenue.  <\/p>\n<\/li>\n<li class=\"yf-1jsc1up\">\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Compass Pathways was added to the index following its final, large-scale trials for COMP360, a synthetic psilocybin treatment that provided three to six months of relief for treatment-resistant depression during clinical trials.  <\/p>\n<\/li>\n<\/ul>\n<p>        <strong>Evolving the HTEC Index Portfolio<\/strong>          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">In order to keep up with what is a fast-moving and complex sector, the team determined that companies should be selected based not only on their revenue purity within 9 strategic subsegments, but also on forward-looking, research-based factors. These include their technological and market leadership, as well as their ongoing levels of investment into their technology.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><strong>See more: <\/strong><a href=\"https:\/\/www.etftrends.com\/disruptive-technology-content-hub\/grail-inc-early-cancer-detection-news-boosts-healthcare-tech-etf-htec\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Grail%20Inc.%20Early%20Cancer%20Detection%20News%20Boosts%20Healthcare%20Tech%20ETF%20HTEC;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Grail Inc. Early Cancer Detection News Boosts Healthcare Tech ETF HTEC&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\"><strong>Grail Inc. Early Cancer Detection News Boosts Healthcare Tech ETF HTEC<\/strong><\/a>  <\/p>\n<p>        <strong>9 Key Subsegments Solving Critical Healthcare Challenges<\/strong>      <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/DBDF2D85623F76018C82BD0D131D69ED4D18B634175D3C322694D6939B4AB281\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fetftrends.com%2F6d99c5f61abf05522dd629c4fa914d04\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"9 Key Subsegments Solving Critical Healthcare Challenges\" height=\"512\" width=\"512\" class=\"yf-lglytj loader\"\/><\/a> 9 Key Subsegments Solving Critical Healthcare Challenges           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Furthermore, the index may add or remove companies every quarter to ensure the portfolio stays aligned with the latest technological advancements. Its integral part in this regular rebalance process was demonstrated on June 19, when three companies that we view as key to the future of healthcare were effectively added to HTEC: <a href=\"https:\/\/etfdb.com\/stock\/CRSP\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:CRISPR%20Therapeutics%20(CRSP);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;CRISPR Therapeutics (CRSP)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">CRISPR Therapeutics (CRSP)<\/a>, <a href=\"https:\/\/etfdb.com\/stock\/3696:HKG\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Insilico%20Medicine%20(3696);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Insilico Medicine (3696)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Insilico Medicine (3696)<\/a>, and <a href=\"https:\/\/etfdb.com\/stock\/CMPS\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Compass%20Pathways%20(CMPS);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Compass Pathways (CMPS)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Compass Pathways (CMPS)<\/a>.  <\/p>\n<p>            <strong>CRISPR Therapeutics: Gene-Editing Pioneers<\/strong>          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">CRISPR Therapeutics is a pioneer in gene-editing technologies. Together with another index constituent, <a href=\"https:\/\/etfdb.com\/stock\/VRTX\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Vertex%20(VRTX);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Vertex (VRTX)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Vertex (VRTX)<\/a>, the company developed CASGEVY, the only viable cure for sickle cell disease and beta-thalassemia.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The treatment extracts the patient&#8217;s own blood stem cells, edits their DNA, and then reintroduces them into the patient&#8217;s body. The CASGEVY market could expand significantly as its global launch approaches and the company seeks approval for pediatric use, which would allow patients to be treated at a much earlier stage of life.  <\/p>\n<p>         <strong>Expanding the CRISPR Pipeline<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The company is also working on other technologies, such as a small interfering RNA (siRNA) therapy to prevent blood clots, and a next-generation allogeneic off-the-shelf CAR-T cell therapy for autoimmune diseases like lupus.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Additionally, its pipeline includes two separate gene-editing therapies: one aiming to permanently lower triglycerides and LDL cholesterol, and another targeting Lp(a). Roughly one in five people globally have elevated levels of Lp(a), which is linked to an increased risk of heart attacks and strokes.  <\/p>\n<p>          <strong>Insilico Medicine: Scaling AI Drug Discovery<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This is the first pure-play AI drug discovery company added to the index. Its core business model focuses on generating drug candidates faster and more cost-effectively than traditional competitors, then partnering with pharmaceutical companies for clinical development.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Additionally, the company licenses its proprietary software to major drugmakers. This is a process that continuously generates data to refine and improve its underlying models.  <\/p>\n<p>       <strong>Pioneering Generative AI Clinical Trials<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Insilico\u00a0was the first company to bring a drug candidate that was both discovered and designed entirely by generative AI into Phase II human clinical trials. Expanding its technological reach, the company recently introduced Science MMAI Gym, an infrastructure designed to train other frontier large language models (LLMs) to perform complex, domain-specific drug discovery tasks.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Currently, the company generates approximately 6 to 8 preclinical candidates (PCCs) per year. It expects to scale revenue generation in 2026 through partnerships originating from both its existing pipeline and new launches. FactSet estimates FY 2026 revenue at $1,287MM, compared to an estimated $440MM in FY 2025, while maintaining strong margins (&gt;80%).  <\/p>\n<p>          <strong>Compass Pathways: Redefining Mental Health Care<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Its core business centers on developing COMP360, a proprietary synthetic psilocybin formulated for treatment-resistant depression (TRD). In final, large-scale human trials, this synthetic version of the psychedelic compound traditionally found in magic mushrooms demonstrated the ability to deliver rapid and durable relief for patients with TRD.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Currently, around 3 million patients in the US suffer from TRD, yet fewer than 5% are treated with medications developed specifically for the condition. Current alternatives entail either daily pills with significant side effects or 30+ clinic visits to receive treatment. The antidepressant benefits of a COMP360 treatment have been shown to last anywhere from three to six months after just one or two dosing sessions.  <\/p>\n<p>       <strong>Regulatory Milestones for COMP360<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Compass is on track to finalize its New Drug Application in the fourth quarter of this year. Following this, the company expects to benefit from a recent White House Executive Order directing the DEA to rapidly expedite the rescheduling of any psychedelic treatment that successfully completes Phase 3 trials. Furthermore, COMP360 has shown promising results in early trials for the treatment of PTSD.  <\/p>\n<p>          <strong>Investing in Practical Healthcare Solutions<\/strong>         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Ultimately, addressing the challenges in healthcare requires identifying the businesses building practical solutions. The HTEC index offers a way to follow these changes.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">By using a methodology focused on the specific technologies and themes that will matter over the next decade, HTEC tracks companies working to make the healthcare system more efficient and effective.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><strong>Related Research:<\/strong>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/etfdb.com\/disruptive-technology-content-hub\/missing-out-healthcare-exposure\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Healthcare%20Exposure%20Focused%20on%20Big%20Pharma%3F%20You&#039;re%20Missing%20Out;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Healthcare Exposure Focused on Big Pharma? You&#039;re Missing Out&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Healthcare Exposure Focused on Big Pharma? You&#8217;re Missing Out<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/etfdb.com\/disruptive-technology-content-hub\/brain-black-box-engineering-question\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:The%20Brain%3A%20From%20Black%20Box%20to%20Engineering%20Problem;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;The Brain: From Black Box to Engineering Problem&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">The Brain: From Black Box to Engineering Problem<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/etfdb.com\/disruptive-technology-content-hub\/ai-revolution-diagnostic\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:The%20AI%20Revolution%20in%20Diagnostic%20Imaging;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;The AI Revolution in Diagnostic Imaging&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">The AI Revolution in Diagnostic Imaging<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Looking for regular updates? <a href=\"https:\/\/offer.vettafi.com\/robo-index-subscribe?__hstc=169852158.a5937a870223035107994ecc6f94a9f1.1738269409719.1761075890108.1761174123104.43&amp;__hssc=169852158.5.1761174123104&amp;__hsfp=1702084950\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:Subscribe%20here%20for%20weekly%20insights%20on%20Healthcare%20Technology%2C%20AI%2C%20and%20Robotics%2C%20delivered%20straight%20to%20your%20inbox.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Subscribe here for weekly insights on Healthcare Technology, AI, and Robotics, delivered straight to your inbox.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">Subscribe here for weekly insights on Healthcare Technology, AI, and Robotics, delivered straight to your inbox.<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">For more news, information, and strategy, <a href=\"https:\/\/etfdb.com\/disruptive-technology-channel\/?__hstc=169852158.a5937a870223035107994ecc6f94a9f1.1738269409719.1761075890108.1761174123104.43&amp;__hssc=169852158.5.1761174123104&amp;__hsfp=1702084950\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:visit%20the%20Disruptive%20Technology%20Content%20Hub;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;visit the Disruptive Technology Content Hub&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\"><strong>visit the Disruptive Technology Content Hub<\/strong><\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">HTEC is the underlying index for the Robo Global Healthcare Technology &amp; Innovation ETF (HTEC) and the L&amp;G Healthcare Technology &amp; Innovation UCITS ETF (DOCT.LN).\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">VettaFi is the index provider for HTEC ETF and DOCT.LN, for which it receives an index licensing fee. However, HTEC ETF and DOCT.LN are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of\u00a0 HTEC ETF and DOCT.LN.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><strong>POPULAR ARTICLES AND RESOURCES FROM ETFTRENDS.COM<\/strong>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.etftrends.com?utm_source=Yahoo&amp;utm_medium=referral&amp;utm_campaign=ReadMore\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-ylk=\"slk:READ%20MORE%20AT%20ETFTRENDS.COM%20%3E;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;READ MORE AT ETFTRENDS.COM &gt;&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\">READ MORE AT ETFTRENDS.COM &gt;<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in&hellip;\n","protected":false},"author":2,"featured_media":554137,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[35151,10723,199277,68213,18,135,475,474,237248,237247,19,155959,17,81257,237249,33613],"class_list":["post-554136","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-autoimmune-diseases","tag-clinical-trials","tag-compass-pathways","tag-crispr-therapeutics","tag-eire","tag-health","tag-health-care","tag-healthcare","tag-healthcare-technology-and-innovation","tag-htec","tag-ie","tag-insilico-medicine","tag-ireland","tag-sickle-cell-disease","tag-skilled-healthcare-workers","tag-treatment-resistant-depression"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116812889992630810","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/554136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=554136"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/554136\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/554137"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=554136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=554136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=554136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}